
    
      Gemcitabine shows promising activity in patients with relapsed lymphoma either administered
      as single agent or in combination with other cytotoxic agents. No trial to date evaluated its
      role in patients with primary Hodgkin's lymphoma. We therefore developed a three-weekly
      regimen based on the standard ABVD regimen.
    
  